OncoMatch/Clinical Trials/NCT06545630
Tumor Antigen-sensitized DC Vaccine for Colorectal Cancer Liver Metastases
Is NCT06545630 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Tumor antigen-sensitized DC vaccine for carcinoma.
Treatment: Tumor antigen-sensitized DC vaccine — The aim of this study is to explore the safety and efficacy of tumor antigen-sensitized DC vaccine in postoperative adjuvant treatment of R0 excision Colorectal Cancer Liver Metastases.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Colorectal Cancer
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
KARNOFSKY 0–1
Demographics
Prior therapy
Must have received: surgery — resection of both primary and metastatic tumors
resection of both primary and metastatic tumors and had NED status after surgery
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06545630 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received surgery.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages